Bizarre Patents
Pillow with retractable umbrella
A pillow assembly having a supporting assembly and a retractable umbrella assembly that is easily transportable and allows a user to support his/her head while covering their face from sunlight.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 4919916 | Treatment of neurotransmitter-linked drug abuse Treatment of the abuse of those addictive drugs whose apparent mode of operation includes first an enhancement of neurotransmitter activity and subsequently a reduction in that activity--and in accompanying pleasurable sensations--to such an extent that a... | 04/24/1990 |
| 4847281 | Method of medical treatment of addiction The invention relates to the use of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one and physiologically acceptable salts and solvates thereof in the relief or prevention of a withdrawal syndrome resulting from addiction... | 07/11/1989 |
| 4834973 | Immunological methods for treating mammals Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoact... | 05/30/1989 |
| 4803208 | Opiate agonists and antagonists Dihydromorphinone compound of the general formula wherein ##STR1## where * indicates binding carbon R1 is an optionally substituted alkyl, alkylene, cycloalkyl, or cycloalkylene R2 is OH or H R3 is OH or OCH3 and R is N.dbd.R4, N--R4, ##STR2## R... | 02/07/1989 |
| 4800209 | Method of alleviating withdrawal symptoms The use of lofexidine and its pharmaceutically acceptable salts in alleviating the adverse symptoms of drug withdrawal, pre-menstrual tension and peri-menopausal flushing is disclosed.... | 01/24/1989 |
| 4797410 | Suppression of withdrawal symptoms in opioid-induced tolerance or dependence A method for suppressing withdrawal symptoms in an opioid-induced tolerant or physically dependent individual is disclosed. The method comprises administering to such individual an effective amount of a calcium channel blocking drug or pharmaceutically ac... | 01/10/1989 |
| 4786653 | Treatment of neurotransmitter-linked drug abuse Treatment of the abuse of those addictive drugs whose apparent mode of operation includes first an enhancement of neurotransmitter activity and subsequently a reduction in that activity--and in accompanying pleasurable sensations--to such an extent that a... | 11/22/1988 |
| 4689332 | Growth regulation and related applications of opioid antagonists A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexo... | 08/25/1987 |
| 4673679 | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration Aliphatic, aromatic, carbonate, carbamate, or sulfonate ester prodrugs of 3-hydroxymorphinans lack the bitter taste of the parent compounds and provide enhanced bioavailability of 3-hydroxymorphinans from buccal, nasal, and sublingual dosage forms.... | 06/16/1987 |
| 4671959 | Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions Described is a method for reducing physiological and/or subjective reactivity to stress in humans being subjected to stress conditions. The method consists of administering to such humans an effective amount of a physiological and/or subjective stress rea... | 06/09/1987 |
| 4670264 | Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions Described is a method for reducing physiological and/or subjective reactivity to stress in humans being subjected to stress conditions. The method consists of administering to such humans an effective amount of a physiological and/or subjective stress rea... | 06/02/1987 |
| 4670463 | Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions Described is a method for reducing physiological and/or subjective reactivity to stress in humans being subjected to stress conditions. The method consists of administering to such humans an effective amount of a physiological and/or subjective stress rea... | 06/02/1987 |
| 4670459 | Method of alleviating withdrawal symptoms The use of lofexidine and its pharmaceutically acceptable salts in alleviating the adverse symptoms of drug withdrawal, pre-menstrual tension and peri-menopausal flushing is disclosed.... | 06/02/1987 |
| 4661492 | Analgesic compositions An analgesic composition in parenteral or sublingual unit dosage form comprising an active dose of buprenorphine and an amount of naltrexone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the ... | 04/28/1987 |
| 4647460 | Composition and method for narcotics withdrawal Physical and emotional symptoms characteristic of withdrawal from narcotics addiction are reduced or eliminated entirely by treatment with a unique combination of naturally-derived ingredients, primarily herbal in origin, the component of highest concentr... | 03/03/1987 |
| 4622244 | Process for preparation of microcapsules Microcapsules particularly those less than 300 microns in size are provided which are adapted for injection by conventional means to afford controlled release of the encapsulated drug material, such as a narcotic antagonist, an antibiotic or the like, ove... | 11/11/1986 |
| 4582835 | Analgesic compositions A method of treating pain which comprises the administration to a patient of a parenterally or sublingually effective dose of buprenorphine together with an amount of naloxone sufficient to prevent substitution in an opiate dependent subject. Preferably w... | 04/15/1986 |
| 4565690 | Method for treating drug addiction A method for treating drug addiction from compounds which cause a catabolic effect on the human body, which comprises administering to said body, a sufficient amount of an anabolic agent containing bivalent negative selenium or sulfur.... | 01/21/1986 |
| 4499096 | Rapid method for interrupting the narcotic addiction syndrome The administration to a heroin addict of ibogaine, ibogaine HCl or other non toxic salts of ibogaine, an alkaloid of the family apocynaceae, has been discovered to unexpectedly interrupt the physiological and psychological aspects of the opiate addiction ... | 02/12/1985 |
| 4362870 | Selective opioid receptor alkylating agents A selective opioid receptor, site-directed alkylating agent useful as a narcotic antagonist and non-addictive analgesic having the formula: ##STR1## wherein R is a Michael acceptor, a haloacetamide or isothiocyanate and R' is cyclopropylmethyl, allyl... | 12/07/1982 |
| 4312878 | Method of eliminating opiate withdrawal symptoms with clonidine in humans A method of eliminating opiate withdrawal symptoms in human opiate addicts by oral administration of clonidine.... | 01/26/1982 |
| 4305860 | Stable, pumpable, solvent-free colloidal polyampholyte latices, their preparation and use in paper Stable, pumpable, solvent-free polyampholyte latices characterized by their colloidal nature, as well as by a solids content of about 10 to 40% by weight and a RVF Brookfield bulk viscosity of up to 20,000 centipoises at 25° C. and 20 RPM, are prepared b... | 12/15/1981 |
| 4126684 | 4-Amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse 4-Amino-3-p-halophenylbutyric acids, acyl derivatives, esters and/or salts thereof reduce addiction liability, particularly that of narcotics, or the withdrawal symptoms observed after interruption of prolonged use of addicting agents, especially of narco... | 11/21/1978 |
| 4124715 | Method of pharmacologically treating drug addiction with fusaric acid A method of pharmacologically alleviating craving for and withdrawal from narcotics and amphetamines in human beings which method comprises administering to a human being a therapeutically effective amount of fusaric acid (5-butyl-picolinic acid). Pharmac... | 11/07/1978 |
| 3996370 | Antagonism of ethanol intoxication with 4[(4,5-dihydro-2-1H-imidazolyl)methoxy]-N,N,2-trimethylbenzenamine A novel method for combatting ethanol intoxication and narcosis in animals by administering an effective amount of the compound 4[(4,5-dihydro-2-1H-imidazolyl)methoxy]-N,N,2-trimethylbenzenamine or a pharmaceutically acceptable salt thereof internally to ... | 12/07/1976 |
| 3980766 | Orally administered drug composition for therapy in the treatment of narcotic drug addiction Drugs which are suitable for such therapy in treatment of narcotic drug addiction by oral use, e.g., methadone, are formulated to prevent injection abuse through concentration of the active component in aqueous solution by incorporating in a solid dosage ... | 09/14/1976 |
| 3975436 | Benzylamine narcotic antagonists A process for antagonizing the pharmacologic effects of a narcotic agent in warm-blooded animals, and compositions for effecting this process are disclosed.... | 08/17/1976 |
| 3966940 | Analgetic compositions Orally effective, analgetic compositions have been developed which are useful in the prevention of drug abuse because upon parenteral administration, they do not produce analgesia, euphoria, or physical dependence. Such compositions comprise an orally act... | 06/29/1976 |
| 3963727 | 1,2 Disubstituted benzimidazole derivatives A compound having the formula: ##SPC1## Wherein R represents a hydrogen atom or a lower alkyl group, and X represents a halogen atom; or the acid-addition salt thereof having a distinctive neuroleptic activity.... | 06/15/1976 |
